Physician profile
Saurin Mehta
NPI 1245394295
$9,164.01
in general payments reported to CMS, 2019-2025
31 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,298 · 2020: $776 · 2021: $344 · 2022: $480 · 2023: $1,278 · 2024: $1,263 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,019 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,019.25 |
| Education | $245.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,285.63 | 2019-2025 | Evenity, Tavneos, Uplizna |
| Abbvie INC. | $1,167.00 | 2019-2025 | |
| Janssen Biotech, INC. | $759.26 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals Lp | $717.51 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $603.31 | 2019-2025 | |
| Ucb, INC. | $581.98 | 2019-2025 | Cimzia, Bimzelx |
| Genentech USA, INC. | $507.27 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Pfizer INC. | $480.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $477.93 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $464.89 | 2019-2025 | Benlysta |
| Genzyme Corporation | $334.20 | 2019-2024 | |
| Lilly USA, LLC | $276.40 | 2019-2025 | Taltz |
| Radius Health, INC. | $195.07 | 2019-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $170.37 | 2019-2025 | Ultomiris |
| Sobi, INC | $162.67 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medexus Pharma, INC. | $146.97 | 2019-2020 | |
| Horizon Therapeutics Plc | $132.91 | 2019-2023 | Krystexxa |
| Celgene Corporation | $103.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $91.69 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $68.24 | 2020 | |
| Kyowa Kirin, INC. | $56.29 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $46.50 | 2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $46.37 | 2023 | Idacio |
| Aurinia Pharma U.S., INC. | $39.38 | 2021 | |
| Depuy Synthes Sales INC. | $31.58 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $26.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.01 | 2019 | |
| Ferring Pharmaceuticals INC. | $23.66 | 2019 | |
| Sandoz INC. | $21.31 | 2024 | Hyrimoz |
| Kiniksa Pharmaceuticals, Ltd. | $19.43 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurin Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.